Vladimir Tolstikov (Presenter)
BERG
Bio: Vladimir Tolstikov, Ph.D., is a Director of Metabolomics at BERG. He received B.S. and M.S in Organic Chemistry in 1977 from M.V. Lomonosov Institute of Fine Chemical Technology, in Moscow, Russia. He received Ph.D. in Organic Chemistry in 1983 from the Institute of Chemical Means for Plant Protection, Moscow, Russia. He is a pioneer in HILIC separations development applied to Metabolomics. During his career he was working in leading research institutions in USA, Germany, Hungary and Russian Federation. Among these institutions are the world renowned Max Plank Institute, UC Davis, Eli Lilly and Company. He has joined BERG in 2014. He is author, contributor and participant of 46 conferences, 5 book chapters, and 56 articles.
Authorship: Vladimir Tolstikov, PhD.
BERG, Framingham, Massachusetts, USA
| Short Abstract Recent advances in mass spectrometry technologies facilitated emerging Omics platforms capable translating biological output into therapeutic candidates. Metabolomics demonstrated tremendous promise in delivering quantitative information on differences in metabolism associated with disease onset/progression and pharmaceutical intervention. At BERG, we have implemented an industrial level high throughput metabolomics platform providing both high quality and depth of information allowing for reliable and broadest capture of the metabolome for the pre-clinical and clinical matrixes analyzed. Platform description and highlights of the BERG’s innovative approach for pharmaceutical development using in-depth patient stratification approaches as well as biology based drugs will be discussed. |
Long Abstract
The pharmaceutical and biotech industries are predominantly the most research-intensive organizations in the United States. These organizations are heavily invested on applying innovative solutions to enhance pipeline development improve patient care. There are several factors that influence health and well-being of patients and the role of altered metabolism in diverse disease indications is emerging as a driving force for therapeutic intervention as well as stratifying patient populations. Currently, due to the rapid advances in mass spectrometry technologies various Omics platforms have emerged that have translated biological output into therapeutic candidates. In this arena, metabolomics has demonstrated tremendous promise in delivering robust quantitative information regarding differences in metabolism associated with disease onset/progression and pharmaceutical intervention. At BERG, we have implemented an industrial level high throughput metabolomics platform providing both high quality and depth of information allowing for reliable and broadest capture of the metabolome for the pre-clinical and clinical matrixes analyzed. Gas chromatography and liquid chromatography are the two major separation techniques complementing each other for deconvoluting very complex mixtures. Description of GC-MS and LC-MS techniques in the global metabolomics platform dedicated for theranostic and clinical studies will be discussed. Highlights of the BERG’s innovative approach for pharmaceutical development using in-depth patient stratification approaches as well as biology based drugs will be discussed.
References & Acknowledgements:
| Description | Y/N | Source |
| Grants | no | |
| Salary | yes | BERG |
| Board Member | no | |
| Stock | no | |
| Expenses | no |
IP Royalty: no
| Planning to mention or discuss specific products or technology of the company(ies) listed above: | yes |